2644results about "Ester active ingredients" patented technology

The invention discloses a method for preparing diglyceride with the effects of reducing blood fat, total cholesterol, blood sugar and uric acid through enzymolysis and a product and application of the diglyceride, and belongs to the technical field of diglyceride production.The method comprises the following steps that 1, vegetable oil, glycerin, compound lipase and water are mixed to be subjected to a glycerolysis reaction, and a reactant is obtained; (2) separating reactants, and collecting supernatant; (3) performing distillation separation on the supernatant, and performing decoloration and deodorization to obtain diglyceride; the vegetable oil in the step (1) is low-erucic acid rapeseed oil and corn oil; the composite lipase in the step (1) is prepared from mucor javanicus lipase, aspergillus niger lipase and aspergillus oryzae lipase in a mass ratio of (2-4): 1: (5-8). According to the invention, the use amount of enzyme can be reduced, the cost is reduced, and the prepared diglyceride has better activity of reducing blood fat, total cholesterol, blood sugar and uric acid, and has more advantages in the preparation of health care products.

Pharmaceutical compositions of epinephrine and its prodrugs are described and the compositions having enhanced active component permeation properties are described as being administered with specific residence times.

The invention belongs to the technical field of grease chemistry, and particularly relates to diglyceride prepared through enzymolysis and used for reducing blood fat, a preparation method and application of the diglyceride. The preparation method comprises the following steps: (1) mixing edible oil, lipase and water, hydrolyzing and dehydrating to obtain a hydrolysate; and (2) mixing the hydrolysate, glycerol and partial glyceride lipase, reacting, and distilling to obtain the diglyceride, the partial glyceride lipase in the step (2) is a mixture of lipase Lipase G50 and lipase Novozyme 435. The diglyceride prepared by the method disclosed by the invention has an excellent effect of reducing blood fat; and the obtained diglyceride is high in yield and low in acid value, and the finished product does not need deacidification treatment, so that the method is suitable for large-scale industrial production.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The present invention relates to a nutritional composition, food and pharmaceutical products comprising the nutritional composition, and uses thereof. The nutritional composition comprises medium and long chain fatty acid triglycerides and breast milk oligosaccharides, and the weight ratio of the medium and long chain fatty acid triglycerides to the breast milk oligosaccharides is 1: 1 to 9: 1. The nutritional composition disclosed by the invention can play a role in synergistically promoting skeletal development and particularly improving bone mineral density.

The invention relates to the technical field of food, in particular to diglyceride for reducing triglyceride, cholesterol and uric acid as well as a biological enzyme preparation method and application of the diglyceride. The preparation method comprises the following steps: (1) adding water and glycerol into vegetable oil, and then adding immobilized lipase to react to obtain a reactant; (2) centrifuging reactants, collecting a light-phase product, carrying out molecular distillation, and collecting a heavy-phase product to obtain diglyceride; the immobilized lipase comprises lipase and a carrier, the carrier comprises loofah sponge, soybean meal and bentonite, and the mass ratio of the loofah sponge to the soybean meal to the bentonite is 1: (2-4): (3-6). The method has the advantages that the effects of reducing triglyceride, total cholesterol and uric acid are relatively good, and the yield and the purity are relatively high.

The invention relates to a nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and nervonic acid in a mass ratio of (3: 1)-(1500: 1), and has a synergistic effect in the aspects of preventing or relieving diarrhea, inhibiting staphylococcus aureus in vivo or in vitro and / or preventing or treating inflammation. The invention also relates to a food product comprising said nutritional composition. The invention also relates to application of the nutritional composition in preparation of products with one or more purposes selected from 1) to 3): 1) preventing or relieving diarrhea; 2) inhibiting staphylococcus aureus in vivo or in vitro; and 3) preventing or treating inflammation.

The invention provides a nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and a milk fat globule membrane in a mass ratio of (2: 1)-(97: 1), and the medium-chain and long-chain fatty acid triglyceride and the milk fat globule membrane have a synergistic effect in the aspects of promoting skeletal development, especially increasing bone mineral density and / or preventing or treating osteogenesis insufficiency and / or osteoporosis.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The invention provides a nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride (MLCT) and milk fat globule membrane (MFGM) in a mass ratio of 2: 1 to 80: 1, and the combination of the two has the effects of synergistically improving diarrhea, inhibiting staphylococcus aureus in vivo or in vitro and / or regulating intestinal flora.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to enhance natural healing ability of a biological body and to treat a disease in a mammal, and to mitigate side effects of cancer treatments.

The invention relates to the technical field of probiotics, in particular to a combined fungicide for improving Alzheimer's disease and application of the combined fungicide. The combined microbial agent is prepared from lactobacillus gasseri LFLG-245 and inactivated Ackermania muciniphila AKKLF (Ackermania muciniphila AKKLF); the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the lactobacillus gasseri LFLG-245 is CGMCC (China General Microbiological Culture Collection Center) No.33952. The lactobacillus gasseri LFLG-245 has the advantages that the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center; the Akkermansia muciniphila AKKLF is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the Akkermansia muciniphila AKKLF is CGMCC (China General Microbiological Culture Collection Center) No.33955. The Akkermansia muciniphila AKKLF disclosed by the invention has the advantages that the Akkermansia muciniphila AKKLF can be applied to the field of biological The combined microbial agent provided by the invention can improve the Alzheimer's disease.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The present invention is in the field of antioxidants and relates to cosmetic or pharmaceutical, preferably dermatological, compositions or homecare product comprising or consisting of a synergistic combination of a specific antioxidant and an effective amount of 1,2-heptanediol and / or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or homecare product, in particular for scavenging reactive oxygen species (ROS), for inhibition matrix metalloproteinases expression and / or for inhibiting interleukin 8 (IL-8) secretion. Additionally, the present invention relates to the use of 1,2-heptanediol and / or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols for enhancing the antioxidative effect of an antioxidant in a cosmetic or pharmaceutical, preferably dermatological, composition or homecare product, and / or for enhancing the antioxidative effect of a cosmetic or pharmaceutical, preferably dermatological, composition upon application.

The invention belongs to the technical field of grease preparation, and particularly relates to a preparation method and application of diglyceride oil with a weight reducing effect. Comprising the following steps: firstly, adding grease into a basic nutrient solution, adding strains for fermentation, and filtering to obtain a glycolysis product; adding glycerol into the glycolysis product, carrying out lipase esterification reaction, and carrying out centrifugal separation to obtain an oil phase; the method comprises the following steps: degrading triglyceride by adopting dominant strain fermentation, then adding glycerol, and carrying out esterification reaction under the action of dominant compound lipase to obtain the diglyceride oil. According to the method, the 1, 3-diglyceride can be selectively generated, the proportion of dominant grease of the 1, 3-diglyceride can be increased, and research shows that the prepared diglyceride oil has good weight reduction and fat reduction effects and has a good application prospect.

The invention discloses a method for preparing uric acid-reducing diglyceride through enzymolysis and a product and application thereof, and belongs to the technical field of diglyceride production, the method comprises the following steps: (1) mixing vegetable oil, glycerol, water and an enzyme preparation for reaction to obtain a reaction solution; (2) standing and layering the reaction liquid, and collecting supernatant; (3) performing distillation separation on the supernatant, and performing decoloration and deodorization to obtain diglyceride; the enzyme preparation in the step (1) is prepared from lipase Lipase, esterase Esterase and phospholipase C in a weight ratio of (5-10): (0.1-0.3): 1. Compared with the prior art, the method disclosed by the invention is simple and low in cost, and the prepared diglyceride has more advantages in the aspect of reducing uric acid.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The invention relates to a nutritional composition, a food containing the nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and nervonic acid, and the medium-chain and long-chain fatty acid triglyceride and the nervonic acid have a synergistic effect in the aspects of improving skeletal development and / or preventing or treating bone diseases.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

Disclosed herein are compositions of matter suitable for use in foods, feeds, pharmaceuticals and cosmetic care products, the compositions of matter comprising a retinoid component and fermentation residues thereof. In embodiments, the retinoid component is present in a weight ratio relative to the fermentation residue of 4: 1 or greater, where the retinoid contains cis-isomer and trans-isomer, where the cis-isomer is present in an amount of less than 3% by weight relative to the entire isomer mixture. Preferably, the composition is bio-based. Also described are biotechnological methods for producing the compositions otherwise described, as well as additional methods for processing such compositions into more stable, more commercially acceptable forms. Finally, foods, feeds, pharmaceuticals, and cosmetic care products incorporating the compositions described herein are also disclosed.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

The compositions comprise medium chain triglyceride (MCT) and at least one ingredient selected from the group consisting of fish oil, L-arginine, vitamin E, vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B1, vitamin B2, folic acid, biotin, vitamin B12, and are formulated for the prevention and / or treatment of a disease or condition associated with muscle decline in a subject in need thereof. Preferably, the subject in need is an individual at risk of or having renal failure, renal dysfunction or / and nephropathy, such as chronic nephropathy, protein energy consumption, end-stage nephropathy, renal failure due to hospitalization in an intensive care unit, acute kidney injury, and the muscle decline is selected from the group consisting of muscle depletion, muscle loss due to renal failure or dysfunction, muscle decline associated with chronic kidney disease, muscle loss due to hospitalization in intensive care units during renal failure, metabolic acidosis during chronic kidney disease, protein energy depletion, or a combination thereof. The method enables the prevention and / or treatment of at least one outcome of a disease or condition associated with muscle decline in a subject at risk of or having renal failure, renal dysfunction or / and kidney disease. The composition and the method can be used to improve the level of at least one amino acid.

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

The disclosure provides methods and compositions for treating pancreatic and hepatic disease such as, pancreatic steatosis, pancreatic cancer, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and hepatic cancer. The provided methods include administering an effective amount of a HIF1-α Pathway Inhibitor or a HIF1-α Inhibitor and an PFKFB3 inhibitor to the subject having or at risk of having pancreatic and / or hepatic disease. The provided methods include administering an effective amount of a HIF1-α Pathway Inhibitor or a HIF1-α Inhibitor and an PFKFB3 inhibitor to the subject having or at risk of having pancreatic and / or hepatic disease.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

Compounds, pharmaceutical compositions, kits, and methods for treating gut motility disorders are herein. Examples of gut motility disorders to which the compounds, pharmaceutical compositions, kits, and methods are directed include achalasia, Hirschspmng's disease, an intestinal pseudo-obstruction, gastroesophageal reflux disease (GERD), functional dysphagia, functional dyspepsia, irritable bowel syndrome (IBS), gastroparesis, functional constipations, functional diarrhea, and fecal incontinence. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.